CN101204392A - Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof - Google Patents
Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof Download PDFInfo
- Publication number
- CN101204392A CN101204392A CNA2007101721604A CN200710172160A CN101204392A CN 101204392 A CN101204392 A CN 101204392A CN A2007101721604 A CNA2007101721604 A CN A2007101721604A CN 200710172160 A CN200710172160 A CN 200710172160A CN 101204392 A CN101204392 A CN 101204392A
- Authority
- CN
- China
- Prior art keywords
- daidzein
- self
- preparation
- microemulsion
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 235000007240 daidzein Nutrition 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 239000004530 micro-emulsion Substances 0.000 title claims description 32
- 239000007788 liquid Substances 0.000 title description 2
- 239000002131 composite material Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000007957 coemulsifier Substances 0.000 claims description 16
- 235000014593 oils and fats Nutrition 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 14
- -1 polyoxyethylene Polymers 0.000 claims description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 6
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 6
- 229940093471 ethyl oleate Drugs 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 2
- 229940031016 ethyl linoleate Drugs 0.000 claims description 2
- 239000010513 hydrogenated corn oil Substances 0.000 claims description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004064 cosurfactant Substances 0.000 abstract 1
- 239000004519 grease Substances 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 27
- 239000002775 capsule Substances 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical group OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000002047 solid lipid nanoparticle Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 208000019736 Cranial nerve disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 2
- 230000008822 capillary blood flow Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000593 microemulsion method Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004939 coking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002515 isoflavone derivatives Chemical group 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an oral preparation composition of a self-emulsified daidzein and a preparation method. The composition is made up of 0.5 through 5 percent daidzein, 30 through 60 percent emulsifier, 10 through 40 percent auxiliary emulsifier and 10 through 30 percent grease. The preparation method is as follows: the daidzein is dissolved in cosurfactant under the temperature ranging from 10 DEG C to 80 DEG C, after being cooled, the daidzein is added with an oil phase and the emulsifier then is stirred uniformly. The invention has the advantages of simple operation and easy preservation. The oral preparation composition of the self-emulsified daidzein in the invention can absorb the water in human gastrointestinal tract after being taken orally, with uniform grain diameter ranging from 10nm to 100nm.
Description
Technical field
The present invention relates to self-emulsifying microemulsion oral formulations of a kind of technical field of pharmaceuticals and preparation method thereof, particularly a kind of daidzein self-emulsifying microemulsion oral formulations and preparation method thereof.
Technical background
Daidzein (daidzein) has another name called daidzein, is leguminous plant effective ingredient such as Chinese medicine Radix Puerariae and Semen Glycines, can be by chemosynthesis or Chinese medicine extraction and isolation technics preparation.Daidzein has expansion hat tremulous pulse, cerebral arteries, peripheral blood vessel and blood capillary; Increase arteria coronaria blood vessel, cerebrovascular, peripheral blood vessel, blood capillary blood flow and circulation; Anticoagulant is removed vasospasm, and cholesterol reducing and blood viscosity weaken vascular resistance; Increase myocardium shrinkage function, improve heart rate, reduce myocardial oxygen consumption, increase blood supply of cardiac muscle; β-adrenoreceptor retardance; Antioxidation, enhancing body resistance are improved the climacteric syndrome, strengthen effects such as calcareous absorption.It is mainly used in treatment hypertension, coronary heart disease and cranial nerve disease, also can be used for preventing and treating sudden deafness, treatment climacteric syndrome, prevention angina pectoris, myocardial infarction, the senile dementia of formation cerebral thrombosis, diseases such as osteoporosis.Daidzein toxicity is lower, is fit to long-term prescription.Daidzein belongs to the isoflavone structure, and poorly water-soluble is fat-soluble also undesirable, commercially available daidzein medicament only limits to oral tablet and capsule at present, absorbs slowly in the body, and bioavailability is very low, thereby influenced the curative effect performance of daidzein, limited its extensively practicality.So be necessary to adopt a kind of novel daidzein oral formulations, make things convenient for the patient.
Through the literature search of prior art is found, people such as Zhao Peng " Chinese Journal of New Drugs " (2007, delivered paper " spray drying method solidifies the research of daidzein solid lipid nanoparticle " on 16:955-958).Adopt nanotechnology that daidzein is made in this article and be used for oral solid lipid nanoparticle with the holdup time in the body that prolongs daidzein; help the raising of interior absorption of daidzein body and curative effect; and the solid lipid nanoparticle suspension is cured as redispersible drying nano grain by spray drying method, improve stability.But the shortcoming that its technology exists is that aerosol apparatus blocks easily.Spray-drying process easily produces wall sticking phenomenon.The result of sticking wall can make medicine for a long time attached to the high-temperature part of equipment, causes coking or fusion, and production can't be carried out, and causes the serious gathering of solid lipid nanoparticle simultaneously.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, daidzein oral preparation composition of a kind of self-microemulsion and preparation method thereof is provided, makes it overcome the above-mentioned defective that background technology exists, the preparation of self-emulsifying microemulsion oral administration system does not need special equipment, simple to operate, and be easy to preserve.
The present invention is achieved by the following technical solutions:
The daidzein oral preparation composition of self-microemulsion involved in the present invention, its component and mass percentage content thereof are:
Daidzein 0.5%-5%
Emulsifying agent 30%-60%
Co-emulsifier 10%-40%
Oils and fats 10%-30%
Described emulsifying agent is selected from a kind of or its mixture in polyethylene glycol glycerol three esters, polyoxyethylene castor oil, polyoxyethylene hydrogenated Oleum Ricini, phospholipid, Tween 80 or the polysorbas20.
Described co-emulsifier is selected from a kind of or its mixture in ethanol, propylene glycol or the Polyethylene Glycol.
Described oils and fats is selected from a kind of or its mixture in ethyl oleate, Ethyl linoleate, Oleum Ricini, Oleum Arachidis hypogaeae semen, hydrogenated corn oil, MCT Oil or the isopropyl myristate.
The preparation method of the daidzein oral preparation composition of self-emulsifying microemulsion involved in the present invention is concrete: under 10-80 ℃ of condition temperature, according to mass percent, daidzein is dissolved in co-emulsifier earlier, after cooling, add oils and fats and emulsifying agent, stirring gets final product.The inventive method is very simple, is easy to preserve.
Take for the ease of the patient, the daidzein oral preparation composition of self-emulsifying microemulsion of the present invention can be adopted method well known in the art canned in capsule, obtain capsule; Or, adopt method well known in the art to be prepared as tablet, capsule, soft capsule, oral liquid, oral administration mixed suspension, oral gel or granule etc. with the daidzein oral preparation composition of self-emulsifying microemulsion of the present invention and medically acceptable carrier.
Described carrier is meant the pharmaceutical carrier of pharmaceutical field routine, as diluent, excipient such as water etc., filler, as starch, sucrose etc., binding agent, as cellulose derivative gelatin, polyethylene pyrrole alkane ketone etc., lubricant is as Pulvis Talci etc.
The daidzein oral preparation composition of self-microemulsion of the present invention can be applied to treat in the aspect medicines such as hypertension, coronary heart disease, angina pectoris, myocardial infarction, cerebral thrombosis, arrhythmia, cranial nerve disease, sudden deafness, osteoporosis, climacteric syndrome.
Compared with prior art, the daidzein oral preparation composition of self-emulsifying microemulsion of the present invention, after oral, absorb the interior moisture of gastrointestinal tract and carry out self-emulsifying microemulsion, formed microemulsion is a kind of transparent, low viscous, each homogeny and thermodynamically stable profit hybrid system, its particle diameter is even, is distributed between 10～100nm.The preparation of self-emulsifying microemulsion oral administration system does not need special equipment, simple to operate, and be easy to preserve, as a kind of novel medicament carrier, the present invention possesses low viscosity, stable, absorb rapidly, characteristics such as target administration, and improve the oral absorption of medicine, bioavailability of medicament is brought up to 2.5 times of contrast suspension, reduces toxic and side effects.
Description of drawings
Fig. 1 is the particle size distribution figure of daidzein microemulsion of the present invention.
Fig. 2 curve chart during for the medicine of the light water suspension of rat of the present invention oral daidzein self-emulsifying microemulsion capsule and daidzein.
The specific embodiment
Below in conjunction with accompanying drawing embodiments of the invention are elaborated: present embodiment is being to implement under the prerequisite with the technical solution of the present invention, provided detailed embodiment and concrete operating process, but protection scope of the present invention is not limited to following embodiment.
The component of the self-emulsifying composition of present embodiment and percentage by weight thereof are: daidzein 1%, emulsifying agent 60%, co-emulsifier 20%, oils and fats 19%.
Described emulsifying agent is a polyoxyethylene hydrogenated Oleum Ricini.
Described co-emulsifier is a PEG400.
Described oils and fats is an ethyl oleate.
The preparation technology of the self-emulsifying composition in the present embodiment is: under 10-80 ℃ of condition temperature, daidzein is dissolved in the PEG400 of recipe quantity earlier, after cooling, press recipe quantity and add polyoxyethylene hydrogenated Oleum Ricini and ethyl oleate, both stir can.
The beneficial effect of present embodiment is: after (1) becomes self-emulsifying composition with medication preparation, be dissolution medium with 0.1M HCl, daidzein self-emulsifying composition 30 minutes can stripping more than 80%.(2) with after 100 times of the self-emulsifying composition dilutions of preparation, the mensuration mean diameter is 21.6nm.Particle size distribution is seen accompanying drawing 1.By accompanying drawing 1 as seen, the particle diameter of this microemulsion system overwhelming majority except that the minority granule meets in the pharmaceutics requirement to microemulsion formulation at 10-100nm.(3) because particle diameter is little, medicine degree of scatter height, thus the degree of absorption of increase medicine improves bioavailability.
Embodiment 2
The component of the self-emulsifying composition of present embodiment and percentage by weight thereof are: daidzein 0.5%, emulsifying agent 55%, co-emulsifier 24.5%, oils and fats 10%.
Described emulsifying agent is a polyoxyethylene castor oil.
Described co-emulsifier is a PEG400.
Described oils and fats is an isopropyl myristate.
The preparation technology of the self-emulsifying composition in the present embodiment is: under 10-80 ℃ of condition temperature, daidzein is dissolved in the PEG400 of recipe quantity earlier, after cooling, press recipe quantity and add polyoxyethylene castor oil and isopropyl myristate, both stir can.
The beneficial effect of present embodiment is: after (1) becomes self-emulsifying composition with medication preparation, be dissolution medium with 0.1M HCl, daidzein self-emulsifying composition 30 minutes can stripping more than 80%.(2) with after 100 times of the self-emulsifying composition dilutions of preparation, particle diameter is less than 100nm.(3) because particle diameter is little, medicine degree of scatter height, thus the degree of absorption of increase medicine improves bioavailability.
Embodiment 3
The component of the self-emulsifying composition of present embodiment and percentage by weight thereof are: daidzein 0.5%, emulsifying agent 60%, co-emulsifier 20%, oils and fats 19.5%.
Described emulsifying agent is a polyoxyethylene castor oil.
Described co-emulsifier is a propylene glycol.
Described oils and fats is an isopropyl myristate.
The preparation technology of the self-emulsifying composition in the present embodiment is: under 10-80 ℃ of condition temperature, daidzein is dissolved in the propylene glycol of recipe quantity earlier, after cooling, presses recipe quantity and add polyoxyethylene castor oil and isopropyl myristate, both stir can.
The beneficial effect of present embodiment is: after (1) becomes self-emulsifying composition with medication preparation, be dissolution medium with 0.1M HCl, daidzein self-emulsifying composition 30 minutes can stripping more than 80%.(2) with after 100 times of the self-emulsifying composition dilutions of preparation, particle diameter is less than 100nm.(3) because particle diameter is little, medicine degree of scatter height, thus the degree of absorption of increase medicine improves bioavailability.
Embodiment 4
The component of the self-emulsifying composition of present embodiment and percentage by weight thereof are: daidzein 3%, emulsifying agent 40%, co-emulsifier 40%, oils and fats 17%.
Described emulsifying agent is a Tween 80.
Described co-emulsifier is a PEG400.
Described oils and fats is an ethyl oleate.
The preparation technology of the self-emulsifying composition in the present embodiment is: under 10-80 ℃ of condition temperature, daidzein is dissolved in the PEG400 of recipe quantity earlier, after cooling, presses recipe quantity and add Tween 80 and ethyl oleate, both stir can.
The beneficial effect of present embodiment is: after (1) becomes self-emulsifying composition with medication preparation, be dissolution medium with 0.1M HCl, daidzein self-emulsifying composition 30 minutes can stripping more than 80%.(2) with after 100 times of the self-emulsifying composition dilutions of preparation, particle diameter is less than 100nm.(3) because particle diameter is little, medicine degree of scatter height, thus the degree of absorption of increase medicine improves bioavailability.
The component of the self-emulsifying composition of present embodiment and percentage by weight thereof are: daidzein 5%, emulsifying agent 35%, co-emulsifier 30%, oils and fats 30%.
Described emulsifying agent is a polyoxyethylene hydrogenated Oleum Ricini.
Described co-emulsifier is a propylene glycol.
Described oils and fats is a MCT Oil.
The preparation technology of the self-emulsifying composition in the present embodiment is: under 10-80 ℃ of condition temperature, daidzein is dissolved in the propylene glycol of recipe quantity earlier, after cooling, press recipe quantity and add polyoxyethylene hydrogenated Oleum Ricini and MCT Oil, both stir can.
The beneficial effect of present embodiment is: after (1) becomes self-emulsifying composition with medication preparation, be dissolution medium with 0.1M HCl, daidzein self-emulsifying composition 30 minutes can stripping more than 80%.(2) with after 100 times of the self-emulsifying composition dilutions of preparation, particle diameter is less than 100nm.(3) because particle diameter is little, medicine degree of scatter height, thus the degree of absorption of increase medicine improves bioavailability.
Embodiment 6
Canned with the compositions daidzein oral preparation composition of embodiment 1 in No. 0 capsule.Measure capsular dissolution with reference to two appendix XC of Pharmacopoeia of the People's Republic of China version in 2005 three therapeutic methods of traditional Chinese medicine.Be dissolution medium with 900mL0.1M HCl or pH6.8PBS respectively, rotating speed is 50rpm, respectively at 5,10,15,30,45,60,90, the 120min timing sampling, and 0.45 μ m filtering with microporous membrane, ultraviolet spectrophotometer is measured daidzein concentration.
The release kilsyth basalt of daidzein self-emulsifying microemulsion capsule of the present invention in different medium sees the following form.As can be seen from the above results, the release there was no significant difference of daidzein self-emulsifying microemulsion capsule in different medium.
| Time (min) | 5 | 10 | 15 | 30 | 45 | 60 | 90 | 120 |
| ?0.1mol/L?HCl ?PH6.8?PBS | 11.08％ 5.42％ | 38.50％ 35.17％ | 52.10％ 56.80％ | 80.28％ 79.12％ | 89.48％ 85.80％ | 92.65％ 88.48％ | 93.62％ 93.40％ | 94.22％ 95.75％ |
Embodiment 7
The capsular bioavailability of daidzein self-emulsifying microemulsion of inventing in order to check has been studied the relative bioavailability of the light water suspension of rat oral daidzein self-emulsifying microemulsion capsule and daidzein, the results are shown in accompanying drawing 2.
The capsular AUC of the oral daidzein self-emulsifying microemulsion of rat is 381.17ng.hour/mL, and the AUC of the light water suspension of daidzein is 955.18ng.hour/mL, and relative bioavailability is 250.6%.This self-microemulsion is compared with common suspension as seen from Figure 3, and the Cmax of self-microemulsion is higher, and it is close with peak time that medicine is eliminated time MRT.
Claims (6)
1. the daidzein oral preparation composition of a self-microemulsion is characterized in that, component and mass percentage content thereof are:
Daidzein 0.5%-5%
Emulsifying agent 30%-60%
Co-emulsifier 10%-40%
Oils and fats 10%-30%.
2. the daidzein oral preparation composition of self-microemulsion according to claim 1, it is characterized in that described emulsifying agent is selected from a kind of or its mixture in polyethylene glycol glycerol three esters, polyoxyethylene castor oil, polyoxyethylene hydrogenated Oleum Ricini, phospholipid, Tween 80 or the polysorbas20.
3. the daidzein oral preparation composition of self-microemulsion according to claim 1 is characterized in that, described co-emulsifier is selected from a kind of or its mixture in ethanol, propylene glycol or the Polyethylene Glycol.
4. the daidzein oral preparation composition of self-microemulsion according to claim 1, it is characterized in that described oils and fats is selected from a kind of or its mixture in ethyl oleate, Ethyl linoleate, Oleum Ricini, Oleum Arachidis hypogaeae semen, hydrogenated corn oil, MCT Oil or the isopropyl myristate.
5. the daidzein oral preparation composition of self-microemulsion according to claim 1 is characterized in that, described compositions, and its particle diameter is even, is distributed between 10～100nm.
6. the preparation method of the daidzein oral preparation composition of a self-microemulsion as claimed in claim 1 is characterized in that, under 10-80 ℃ of condition temperature, by mass percentage, daidzein is dissolved in co-emulsifier earlier, after cooling, add oils and fats and emulsifying agent, stir.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101721604A CN101204392A (en) | 2007-12-13 | 2007-12-13 | Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101721604A CN101204392A (en) | 2007-12-13 | 2007-12-13 | Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101204392A true CN101204392A (en) | 2008-06-25 |
Family
ID=39565021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101721604A Pending CN101204392A (en) | 2007-12-13 | 2007-12-13 | Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101204392A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632650A (en) * | 2009-07-07 | 2010-01-27 | 沈阳药科大学 | Self-microemulsifying semisolid skeleton capsule of daidzein and preparation method thereof |
| CN102008454A (en) * | 2010-12-03 | 2011-04-13 | 上海交通大学 | Daidzein-entrapped PLGA nanoparticles and preparation method thereof |
| CN102258475A (en) * | 2010-05-28 | 2011-11-30 | 中国科学院上海药物研究所 | Daidzein solid lipid nanoparticles and preparation method thereof |
| CN102475700A (en) * | 2010-11-25 | 2012-05-30 | 四川科伦药物研究有限公司 | Daidzein concentrated solution and special diluent thereof |
| CN102114245B (en) * | 2009-12-31 | 2012-11-07 | 四川科伦药物研究有限公司 | Special solvent for daidzein pre-emulsified injection, preparation method and application thereof |
| CN102114012B (en) * | 2009-12-31 | 2013-10-16 | 四川科伦药物研究有限公司 | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method and application thereof |
| CN104784158A (en) * | 2015-04-03 | 2015-07-22 | 上海交通大学 | PLGA (poly (lactic-co-(glycolic) acid) electrospinning fiber loaded with daidzein NLCs (nanostructure lipid carriers) as well as preparation method |
-
2007
- 2007-12-13 CN CNA2007101721604A patent/CN101204392A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632650A (en) * | 2009-07-07 | 2010-01-27 | 沈阳药科大学 | Self-microemulsifying semisolid skeleton capsule of daidzein and preparation method thereof |
| CN101632650B (en) * | 2009-07-07 | 2013-11-27 | 沈阳药科大学 | Self-microemulsifying semisolid skeleton capsule of daidzein and preparation method thereof |
| CN102114245B (en) * | 2009-12-31 | 2012-11-07 | 四川科伦药物研究有限公司 | Special solvent for daidzein pre-emulsified injection, preparation method and application thereof |
| CN102114012B (en) * | 2009-12-31 | 2013-10-16 | 四川科伦药物研究有限公司 | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method and application thereof |
| CN102258475A (en) * | 2010-05-28 | 2011-11-30 | 中国科学院上海药物研究所 | Daidzein solid lipid nanoparticles and preparation method thereof |
| CN102258475B (en) * | 2010-05-28 | 2013-05-22 | 中国科学院上海药物研究所 | Daidzein solid lipid nanoparticles and preparation method thereof |
| CN102475700A (en) * | 2010-11-25 | 2012-05-30 | 四川科伦药物研究有限公司 | Daidzein concentrated solution and special diluent thereof |
| CN102008454A (en) * | 2010-12-03 | 2011-04-13 | 上海交通大学 | Daidzein-entrapped PLGA nanoparticles and preparation method thereof |
| CN102008454B (en) * | 2010-12-03 | 2012-07-04 | 上海交通大学 | Daidzein-entrapped PLGA nanoparticles and preparation method thereof |
| CN104784158A (en) * | 2015-04-03 | 2015-07-22 | 上海交通大学 | PLGA (poly (lactic-co-(glycolic) acid) electrospinning fiber loaded with daidzein NLCs (nanostructure lipid carriers) as well as preparation method |
| CN104784158B (en) * | 2015-04-03 | 2017-10-31 | 上海交通大学 | The PLGA Electrospuns and preparation method of Daidzein nano structured lipid carrier |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105816423B (en) | edaravone dosage form | |
| JP3903061B2 (en) | Nanoparticles containing drug, method for producing the same, and preparation for parenteral administration comprising the nanoparticles | |
| CN101204392A (en) | Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof | |
| CN107308133A (en) | Curcumin pharmaceutical preparation | |
| JPWO2003004003A1 (en) | Soft capsule | |
| CN101991593A (en) | Application of quercetin in medicament preparation | |
| CN102824356A (en) | Baicalin nano crystal suspension, nano crystal dry powder and methods for preparing baicalin nano crystal suspension and nano crystal dry powder | |
| CN101028274A (en) | Ursodeoxycholic acid preparation in treatment of hepatobiliary diseases and its making method | |
| US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
| CN112915121A (en) | Cannabinoid nano micelle preparation and preparation method thereof | |
| US11013694B2 (en) | Formulation of a micro drop pill and the preparation method thereof | |
| US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
| CN1863523A (en) | Application of levo-butylphthalide in preparing medicine for preventing and treating cerebral infarction | |
| CN112022919A (en) | Percutaneous-absorption artemisia vulgaris oil carrier gel and preparation method thereof | |
| CN101088523A (en) | Nanometer solid lipid particle of active skullcap components and its prepn process and prepn | |
| CN101108872A (en) | Plants natural base extractive and formulated product and use thereof | |
| CN101045045A (en) | Medicine composition containing soya bean aglycone and its preparing method | |
| CN103505414B (en) | Butylphthalide nasal drop and preparation method thereof | |
| CN101088505B (en) | Nanometer breviscapine polymer particle preparation and its preparation process | |
| CN105997927A (en) | Oryzanol nanocrystal capsule preparation and preparation process thereof | |
| CN101998828A (en) | Pharmaceutical solutions and method for solubilizing therapeutic agents | |
| CN1899275B (en) | Use of composition of rheinic acid or rheinic acid compounds in preparing medicine for treating osteoarthritis | |
| Saleemi et al. | Phytosomes used for herbal drug delivery | |
| TWI351399B (en) | Pharmaceutical formulations and compositions of a | |
| CN101422454B (en) | Omega-3 polyunsaturated fatty acid tanshinone IIA sub-microemulsion and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080625 |